natgillin/translations-raw huggingface dataset:
Potactasol не се препоръчва в случай на сериозно увреждане на черния дроб; ако страдате от възпаление на белия дроб с признаци като кашлица, повишена температура и затруднено дишане, вижте също точка 4 „Възможни нежелани реакции”
Potactasol is not recommended in case of severe liver impairment; if you suffer from lung inflammation with signs such as cough, fever and difficulties in breathing, see also section 4 “Possible side effects”.
Potactasol се предлага в картонени кутии, съдържащи 1 флакон.
Potactasol is available in cartons containing 1 vial.
Potactasol се предлага във флакони от безцветно стъкло тип I със сива бромбутилова запушалка и алуминиева обкатка с отчупващо се пластмасово капаче.
Potactasol is supplied in type I colourless glass vials with grey bromobutylic stopper and aluminium seals with plastic flip-off caps.
Potactasol се прилага за лечение на:
Potactasol is used to treat:
Potactasol съдържа активното вещество топотекан, което помага за унищожаване на туморни клетки.
Potactasol contains the active substance topotecan which helps to kill tumour cells.
Potactasol флакони 1 mg трябва да бъдат разтворени с 1,1 ml вода за инжекции.
Potactasol 1 mg vials must be reconstituted with 1.1 ml water for injections.
Potactasol флакони 4 mg трябва да бъдат разтворени с 4 ml вода за инжекции.
Potactasol 4 mg vials must be reconstituted with 4 ml water for injections.
Potah:
Coating:
Potahovaná tableta
Film-coated tablet
Potahovaná tableta.
Film-coated tablet.
potahované tablety) 400 mg
capsules) 400 mg single dose
Potahová vrstva – hypromelóza (hydroxypropylmethylcelulóza, E464), oxid titaničitý (E171), mastek (E553b), triacetin (E1518), červený oxid železitý (E172)
Film-coating - hypromellose (hydroxypropyl methyl cellulose, E464), titanium dioxide (E171), talc (E553b), triacetin (E1518), red iron oxide (E172)
Potassium dihydrogen phosphatec (E340i)
Sodium chlorided
Potem potisnite bat noter, da boste iz brizge iztisnili ves zrak (ampak nič tekočine).
Then press the plunger until all of the air (but none of the liquid) has been removed
Potencialne učinke pramipeksola na reproduktivni sistem so raziskovali pri podganah in zajcih.
The potential effects of pramipexole on reproductive function have been investigated in rats and rabbits.
Potenciální účinky tohoto léčiva na srdce u lidí nelze vyloučit (viz body 4.4 a 4.8).
Potential cardiac effects of this product in humans cannot be ruled out (see sections 4.4 and 4.8).
Potentnost difosfonatov (večje tveganje pri visoko potentnih učinkovinah), pot uporabe (večje tveganje pri parenteralni uporabi) in kumulativni odmerek difosfonata.
Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate.
potovalna bolezen
motion sickness
Potrebna je previdnost pri dajanju zdravila INOmax hkrati z zdravili, ki vsebujejo prilokain.
Care must be taken when INOmax is given at the same time as medicinal products containing prilocaine.
Potrebno je preveriti bolnikov tip kože.
The patient should be screened for skin type
Potters Bar Hertfordshire
Potters Bar Hertfordshire EN6 1TL
Potters Bar Hertfordshire EN6 1TL
Potters Bar Hertfordshire EN6 1TL UK
Potters Bar Hertfordshire EN6 1TL
Station Close Potters Bar Hertfordshire EN6 1TL
Potters Bar Hertfordshire EN6 1TL Великобритания
Potters Bar Hertfordshire EN6 1TL United Kingdom
Potters Bar Hertfordshire, EN6 1TL Великобритания.
Potters Bar Hertfordshire EN6 1TL United Kingdom
Potters Bar, Hertfordshire, EN6 1 TL, Великабритания
Potters Bar, Hertfordshire, EN6 1TL, UK
Potters Bar, Hertfordshire, EN6 1 TL, Великобритания
Potters Bar, Hertfordshire, EN6 1TL, UK
Potters Bar, Hertfordshire, EN6 1TL,
Potters Bar Hertfordshire EN6 1TL
Potters Bar, Hertfordshire, EN6 1TL,
Potters Bar, EN6 1TL,
Potters Bar, Hertfordshire, EN6 1TL,
Potters Bar, Hertfordshire, EN6 1TL
Potters Bar, Hertfordshire, EN6 1TL, Великобритания
Potters Bar, Hertfordshire, EN6 1TL, UK
Potters Bar, Hertfordshire, EN6 1TL, Великобритания.
Potters Bar, Hertfordshire, EN6 1TL, UK
Poté má následovat sledování každých 6 měsíců s častějším sledováním po každé úpravě dávky.
6 monthly monitoring should follow thereafter, with more frequent monitoring following any dose adjustment.
Poté má následovat sledování každých 6 měsíců, s častějším sledováním po jakékoliv úpravě dávky (viz bod 4.4).
6 monthly monitoring should follow thereafter, with more frequent monitoring following any dose adjustments (see section 4.4).
Poté má následovat sledování každých 6 měsíců, s častějším sledováním po jakékoliv úpravě dávky.
6 monthly monitoring should follow thereafter, with more frequent monitoring following any dose adjustment.
potřeba častého močení (polakisurie)
need to urinate frequently (pollakiuria)
Poulvac E. coli лиофилизат за суспензия за спрей ваксинация за пилета и пуйки или за прилагане с водата за пиене при пилета
Poulvac E. coli lyophilisate for suspension for spray vaccination for chickens and turkeys or for use in drinking water for chickens
Poulvac E. coli лиофилизат за суспензия за спрей ваксинация на пилета и пуйки или за прилагане с водата за пиене при пилета
Poulvac E. coli lyophilisate for suspension for spray vaccination for chickens and turkeys or for use in drinking water for chickens
Poulvac E. coli се предлага под формата на изсушен чрез замразяване прах (лиофилизат), от който може да се приготви суспензия.
Poulvac E. coli is available as a freeze dried powder (lyophilisate) which can be made into a suspension.
Poulvac FluFend H5N3 RG инжекционна емулсия за пилета и патици
Poulvac FluFend H5N3 RG emulsion for injection for chickens and ducks
POUŽITELNOST
EXPIRY DATE
Použití přípravku EVOTAZ lze zvažovat během těhotenství pouze tehdy, pokud potenciální přínos převáží potenciální riziko.
The use of EVOTAZ may be considered during pregnancy only if the potential benefit justifies the potential risk.
Použití přípravku EVOTAZ u dětí a dospívajících dosud nebylo zkoumáno.
The use of EVOTAZ in children and adolescents has not yet been studied.
Použití u dětí
Paediatric patients
Používané
Used to treat
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Klopidogrel Teva Pharma B.V. in acetilsalicilne kisline.
You should have been told that ‘oral anticoagulants’ are more effective than acetylsalicylic acid or the combined use of Clopidogrel Teva Pharma B.V. and acetylsalicylic acid for this condition.
Povejte mu, če pijete veliko alkohola (če zaužijete več kot priporočeno dnevno količino; če ste negotovi se posvetujet z zdravnikom ali farmacevtom) ali če ste kadarkoli imeli bolezen jeter.
Tell your doctor if you drink large amounts of alcohol (if you drink more than the recommended daily amount; ask your doctor or pharmacist if you are unsure) or have ever had liver disease.
Povejte svojemu zdravniku ali bolnišničnemu farmacevtu, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Povejte zdravniku, če ste sami ali vaši družinski člani/negovalec opazili, da se pri vas razvijata manija (agitacija, vznesenost ali prevelika vznemirjenost) ali delirij (zmanjšano zavedanje, zmedenost, izguba občutka za resničnost).
Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion, loss of reality).
povečana količina sečnine v
Blood urea increased
Povečanje NO2 lahko povzroči akutne poškodbe pljuč.
Elevated NO2 may cause acute lung injury.
Povečanje simptomov.
Augmentation.
Povečanje telesne mase.
Weight increase.
Povečanje vrednosti AUC∞, AUCt in Cmax znaša 111,88 %, 114,06 % in 115,28 %.
The increase in AUC∞, AUCt, and Cmax is of 111.88%, 114.06%, and 115.28% respectively.
Povečano znojenje.
Increased sweating.
Povišana telesna temperatura ali okužba (pogosto): če se pojavi temperatura 38 ºC ali višja, znojenje ali drugi znaki okužbe (ker imate lahko manj belih krvničk kot normalno, kar je zelo pogosto).
Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection (since you might have fewer white blood cells than normal which is very common).
povišana telesna temperatura, spremembe ravni določenih snovi v krvi ali urinu.
Changes in levels of certain substances in your blood or urine.
Povišanje SGOT (AST)
AST (SGOT)
Povišanje SGOT (AST)
SGOT (AST) elevation
Povišanje SGPT (ALT)
ALT (SGPT)
Povišanje SGPT (ALT)
SGPT (ALT) elevation
Povprečen čas, potreben za doseganje najvišje koncentracije methemoglobina pri teh 13 bolnikih, je bil 10 ± 9 (SD) ur (mediana, 8 ur); en bolnik pa ni presegel 7 % do 40 ur.
The average time to reach peak methaemoglobin was 10 ± 9 (SD) hours (median, 8 hours) in these 13 patients; but one patient did not exceed 7 % until 40 hours.
Povprečje AUC0-inf in Cmax za 5-FU je znašalo približno 3-krat več pri uporabi zdravila Teysuno (50 mg, izraženo z vsebnostjo tegafurja) kot pri samostojni uporabi tegafurja (800 mg), medtem ko sta bili vrednosti AUC0-inf in Cmax za 5-FU presnovek α-fluoro-β-alanine (FBAL) približno 15- do 22--krat nižji pri uporabi zdravila Teysuno kot pri uporabi tegafurja.
Mean AUC0-inf and Cmax for 5-FU were approximately 3-fold greater following administration of Teysuno (50 mg expressed as tegafur content) than following administration of tegafur alone (800 mg), while AUC0-inf and Cmax values for the 5-FU metabolite α-fluoro-β-alanine (FBAL) were approximately 15- to 22-fold lower following administration of Teysuno than following administration of tegafur.
Povprečje AUC0-inf in Cmax za 5-FU je znašalo približno 3-krat več pri uporabi zdravila Teysuno (50 mg, izraženo z vsebnostjo tegafurja) kot pri samostojni uporabi tegafurja (800 mg), medtem ko sta bili vrednosti AUC0-inf in Cmax za 5-FU presnovek α-fluoro-β-alanine (FBAL) približno 15- do 22-krat nižji pri uporabi zdravila Teysuno kot pri uporabi tegafurja.
Mean AUC0-inf and Cmax for 5-FU were approximately 3-fold greater following administration of Teysuno (50 mg expressed as tegafur content) than following administration of tegafur alone (800 mg), while AUC0-inf and Cmax values for the 5-FU metabolite α-fluoro-β-alanine (FBAL) were approximately 15- to 22-fold lower following administration of Teysuno than following administration of tegafur.
Povprečna največja koncentracija nespremenjenega klopidogrela v plazmi (približno 2,2–2,5 ng/ml po enem 75-mg peroralnem odmerku) se je pojavila približno 45 minut po odmerjanju.
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Povprečna ocena CHADS2 je bila 2,0 (razpon: od 0 do 6).
The mean CHADS2 score was 2.0 (range 0-6).
Povprečna sprememba BPI od izhodišča
BPI mean change from baseline
Povprečna stopnja odzivnosti je bila 14,1 %.
The overall response rate was 14.1%.
Povprečna vrednost (%)  SEb
Mean (%) SEb
Povprečna vrednost največje koncentracije snovi 5-FU v plazmi (Cmax) in površina pod krivuljo koncentracije v odvisnosti od časa (AUC) sta bili približno 3-krat večji po uporabi zdravila Teysuno kot po uporabi zgolj tegafurja, čeprav je odmerek zdravila Teysuno 16-krat manjši (50 mg tegafurja) v primerjavi s samostojnim odmerkom tegafurja (800 mg), kar se pripisuje gimeracilu, ki zavira DPD.
Mean 5-FU maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) values were approximately 3-fold higher after Teysuno administration than after administration of tegafur alone, despite a 16-fold lower Teysuno dose (50 mg of tegafur) compared to tegafur alone (800 mg), and are attributed to inhibition of DPD by gimeracil.
Povprečne spremembe od izhodiščne vrednosti do 12. tedna v odstotkih
Mean percent changes from baseline to week 12
Povprečni čas med paliativno oskrbo s spojem in prvo uporabo raziskovanega zdravila je bil 20 dni.
The mean time between shunt palliation and first administration of study medicinal product was 20 days.
Povratna reakcija je najpogostejši neželeni učinek, povezan s klinično uporabo zdravila INOmax.
Rebound reaction is the most commonly adverse reaction in association with the clinical use of INOmax.
Povratna reakcija lahko nastopi na začetku zdravljenja ali kasneje med zdravljenjem.
The rebound may be seen early as well as late during therapy.
Površina pod krivuljo je naraščala približno sorazmerno z velikostjo odmerka.
Area under the curve increased approximately in proportion to the increase in dose.
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
SUMMARY OF PRODUCT CHARACTERISTICS
Povzetek glavnih značilnosti zdravila in navodilo za uporabo zdravila INOmax
Summary of Product Characteristics and Patient Information Leaflet for INOmax
Povzetek glavnih značilnosti zdravila,
Summary of product characteristics
Povzetek neželenih učinkov s pofrimer-natrijem
Summary of adverse reactions with porfimer sodium
Povzetek neželenih učinkov, prikazan v preglednici
b Tabulated summary of adverse events
Povzetek neželenih učinkov, prikazan v preglednici
Tabulated summary of adverse reactions
Povzetek varnostnega profila
Summary of safety profile
Povzetek varnostnih značilnosti
Summary of the safety profile
povzročajo bakterije, s fusidno kislino: dokler uporabljate to zdravilo, ne jemljite fusidne kisline (zdravila za bakterijske okužbe).
Fusidic acid: do not take fusidic acid (a medicine for bacterial infections) while using this medicine.
Poznan Полша
60-322 Poznan Poland
Poznańska 12 05-850 Ożarów Mazowiecki Полша
Poznańska 12 05-850 Ożarów Mazowiecki Poland
Pozornost je treba nameniti možnemu pojavu hipomagneziemije med zdravljenjem.
Attention should also be paid to the possibility of hypomagnesaemia developing during treatment.
Pozorovala sa jedna centrálne potvrdená čiastočná odozva (partial response, PR): celkový podiel s odozvou: 2,5 % CI 95 % (0,1 %- 13,2 %).
One partial response (PR) centrally confirmed was observed: overall RR: 2.5% CI95% (0.1%-13.2%).
Pozri časť 4.
See section 4.
Počas liečby trabektedínom treba sa vyhýbať spotrebe alkoholu vzhľadom na hepatotoxicitu tohto lieku (pozri časť 4.4).
Alcohol consumption must be avoided during treatment with trabectedin due to the hepatotoxicity of the medicinal product (see section 4.4).
Počasi umaknite palec z glave bata, da se prazna brizga pomakne navzgor, dokler ni cela igla prekrita s ščitnikom, kot je prikazano na Sliki 7:
Slowly take your thumb off the plunger head to allow the empty syringe to move up until the entire needle is covered by the needle guard, as shown by Figure 7:
Počasno bitje srca.
Slow heart beat.
Počet krvných doštičiek  100 000/mm3
Platelet count  100,000/mm3
Počkejte na další dávku a vezměte si ji v obvyklou dobu.
Wait and take the next dose at the usual time.
Poškodbe in zastrupitve in zapleti pri posegih
Injury, poisoning and procedural complications
Poškodbe zastrupitve in zapleti pri posegih Pogoste: Bolečina po posegu, abrazija Občasne: Mehurji, krvavitev po posegu
Injury poisoning, and procedural complications Common: Post procedural pain, abrasion Uncommon: Blister, post procedural haemorrhage
Poškodbe zastrupitve in zapleti pri posegih Pogoste: Bolečina po posegu, abrazija Občasne: Mehurji, krvavitev po posegu
Injury, poisoning, and procedural complications Common: Post procedural pain, abrasion Uncommon: Blister, post procedural haemorrhage
Požadavky při užívání antikoncepce
Contraception requirements
Požadovaný objem vypočítajte nasledovne:
Calculate the required volume as follows:
Požádejte svého lékaře nebo lékárníka, pokud potřebujete další informace nebo radu.
Ask your doctor or pharmacist if you need more information or advice.
PP (per protocol) популация
PP (per protocol) Population
PP = Популация според протокола (Per Protocol); ITT = Популация с намерение за лечение (Intent To Treat)
PP = Per Protocol Population; ITT = Intent To Treat Population
PP = Популация според протокола; ITT = Популацията на всички рандомизирани участници
PP = Per Protocol Population; ITT = Intent To Treat Population
PP MANUFACTURING CORPORATION
175 crossing Boulevard,
PP популация*
PP-population
PPAR агонист и метформин, когато използването на PPAR агонист е подходящо и когато с диета и упражнения, плюс двойна терапия с тези лекарствени продукти, не се постига задоволителен гликемичен контрол.
a PPAR agonist and metformin when use of a PPAR agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
PR = прогестеронов рецептор a ER/PR- отрицателен или степен 3 или големина на тумора > 5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size > 5 cm
PR = прогестеронов рецептор а ER/PR-отрицателен или степен 3 или големина на тумора >5 cm
PR = progesterone receptor a ER/PR-negative or Grade 3 or tumor size >5 cm
PR bola u pacienta s alveolárnym rabdomyosarkómom.
The PR corresponded to a patient with an alveolar rhabdomyosarcoma.
PR intervalu.
in the maximum PR interval
PR интервал
PR interval
PR интервали от > 200 msec са наблюдавани при 3 % от лицата в групата на активна контрола (моксифлоксацин) и при 5 % в групата на плацебо.
PR intervals of > 200 msec were seen in 3% of subjects in the active control group (moxifloxacin) and 5% in the placebo arm.
Pr. dosis af 0,2 ml vaccine:
Per dose of 0.2 ml vaccine:
PRAC е на мнение, че не са необходими допълнителни мерки за минимизиране на риска, но новите данни налагат актуализация на предупреждението, за да може то да обхване всички други съдови лезии на лакътя, които настъпват при деца, с цел кожните лезии да бъдат по-добре отразени и охарактеризирани в КХП.
The PRAC considers that no further risk minimization measures are necessary but the new data warrant an update of the warning so that is expanded to any other vascular elbow lesions occurred among children in order to better reflect and characterize skin lesions in the SmPC.
PRAC е на мнение, че са налице достатъчно доказателства, водещи до заключението, че тежки инфекции по време на лечението с терифлуномид могат да доведат до сепсис.
The PRAC is of the opinion that there is enough evidence leading to the conclusion that severe infections during teriflunomide treatment can result to sepsis.
PRAC заключи, че рискът от остеонекроза (или смърт на костна тъкан) на челюстта остава много нисък, но препоръча редица мерки за свеждане на риска до минимум.
The PRAC concluded that the risk of osteonecrosis (or death of bone tissue) in the jaw remains very low, but has recommended a number of measures to minimise the risk.
PRAC обаче счита, че не е ясно дали денят на отрицателния тест за бременност се брои като ден 0 или като ден 1.
However, the PRAC considered unclear if the day of negative pregnancy test is counted as day 0 or as day 1.
PRAC отбелязва, че терифлуномид не може да бъде изключен като възможна причина в случаите, за които е налична информация за времето до начало на проявите, прекъсване/възобновяване и прекратяване на приема на терифлуномид.
The PRAC observed that teriflunomide could not be excluded from potential causal association in cases where time to onset, de-challenge/rechallenge information and discontinuation were available.
PRAC препоръчва актуализиране на продуктовата информация, с цел да се информират медицинските специалисти и пациентите за възможността от поява на тези нежелани реакции.
The PRAC recommended updating the product information to inform health professionals and the patients of the potential for these adverse events.
PRAC препоръчва преди започване и по време на терапията с талидомид пациентите да бъдат оценени за признаци и симптоми на подлежащо сърдечно-белодробно заболяване.
The PRAC recommends that patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease prior to initiating and during thalidomide therapy.
PRAC счита, че продуктовата информация за арипипразол трябва да бъде актуализирана, за да включва нежеланата реакция „хълцане” в точка 4.8 на КХП, тъй като допринасящата роля на арипипразол за съобщените случаи не би могла да бъде изключена.
The PRAC considered that the product information of aripiprazole should be updated to include the adverse event ‘Hiccups” in section 4.8 of the SmPC, since a contributory role of aripiprazole in the reported cases could not be ruled out.
PRAC счита, че случаите на изчезване на симптома при липса на провокация и поява отново при повторна провокация, са важно доказателство за наличие на причинно-следствена връзка, която допринася за потвърждаване на сигнала, свързан с безопасността.
The PRAC considered the cases of dechallenge and rechallenge to be important causal relationship information that contributes to confirm the safety signal.
Prac-tic 137,5 mg Pyriprole
Prac-tic 137.5 mg Pyriprole
Prac-tic 137,5 mg разтвор за локална употреба (спот-он) за малки кучета
Prac-tic 137.5 mg spot-on solution for small dogs
Prac-tic 275 mg разтвор за локална употреба (спот-он) за средни кучета
Prac-tic 275 mg spot-on solution for medium dogs
Prac-tic 56,25 mg Pyriprole
Prac-tic 56.25 mg Pyriprole
Prac-tic 56,25 mg разтвор за локална употреба (спот-он) за много малки кучета
Prac-tic 56.25 mg spot-on solution for very small dogs
Prac-tic 625 mg разтвор за локална употреба (спот-он) за големи кучета
Prac-tic 625 mg spot-on solution for large dogs
Prac-tic не трябва да бъде изхвърлян във водни басейни, тъй като това може да бъде опасно за риби или други водни организми.
Prac-tic should not enter water courses as it may be dangerous for fish and other aquatic organisms.
Prac-tic не трябва да бъде изхвърлян във водни басейни, тъй като това може да бъде опасно за риби или други водни организми.
Prac-tic should not enter water courses as this may be dangerous for fish and other aquatic organisms.
Prac-tic разтвор за локална употреба (спот-он) за кучета
Prac-tic spot-on solution for dogs
Prac-tic разтвор за локална употреба за кучета Pyriprole
Prac-tic spot-on for dogs Pyriprole
Prac-tic разтвор за локална употреба за кучета Pyriprolе
Prac-tic spot-on for dogs Pyriprole
Praceta Jaime Corteção Nº 1 – R/C Loja Esq.
Sant Hipòlit, km 71 E-08503 Gurb-Vic
Pradaxa 110 mg (приложимо за картонената опаковка, не е приложимо за етикета на бутилката)
Pradaxa 110 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 110 mg са твърди капсули със светлосиня непрозрачна капачка и кремаво непрозрачно тяло.
Pradaxa 110 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 110 mg твърди капсули
Pradaxa 110 mg hard capsules
Pradaxa 110 mg твърди капсули Дабигатран етексилат
Pradaxa 110 mg hard capsules Dabigatran etexilate
Pradaxa 110 mg твърди капсули дабигатран етексилат (dabigatran etexilate)
Pradaxa 110 mg hard capsules dabigatran etexilate
Pradaxa 150 mg (приложимо за картонената опаковка, не е приложимо за етикета на бутилката)
Pradaxa 150 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 150 mg са твърди капсули със светлосиня непрозрачна капачка и кремаво непрозрачно тяло.
Pradaxa 150 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 150 mg твърди капсули
Pradaxa 150 mg hard capsules
Pradaxa 150 mg твърди капсули Дабигатран етексилат
Pradaxa 150 mg hard capsules Dabigatran etexilate
Pradaxa 150 mg твърди капсули дабигатран етексилат (dabigatran etexilate)
Pradaxa 150 mg hard capsules dabigatran etexilate
Pradaxa 75 mg (приложимо за картонената опаковка, не е приложимо за етикета на бутилката)
Pradaxa 75 mg (only applicable for folding box, not applicable for bottle label)
Pradaxa 75 mg са твърди капсули със светлосиня непрозрачна капачка и кремаво непрозрачно тяло.
Pradaxa 75 mg are hard capsules with an opaque, light blue-coloured cap and an opaque, cream-coloured body.
Pradaxa 75 mg твърди капсули
Pradaxa 75 mg hard capsules
Pradaxa 75 mg твърди капсули Дабигатран етексилат
Pradaxa 75 mg hard capsules Dabigatran etexilate